HUE026820T2 - The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders - Google Patents

The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders Download PDF

Info

Publication number
HUE026820T2
HUE026820T2 HUE07804842A HUE07804842A HUE026820T2 HU E026820 T2 HUE026820 T2 HU E026820T2 HU E07804842 A HUE07804842 A HU E07804842A HU E07804842 A HUE07804842 A HU E07804842A HU E026820 T2 HUE026820 T2 HU E026820T2
Authority
HU
Hungary
Prior art keywords
compound
compounds
cell
treatment
ppg
Prior art date
Application number
HUE07804842A
Other languages
English (en)
Hungarian (hu)
Inventor
Eliahu Kaplan
Original Assignee
Novaremed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ltd filed Critical Novaremed Ltd
Publication of HUE026820T2 publication Critical patent/HUE026820T2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE07804842A 2006-05-09 2007-05-09 The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders HUE026820T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79910306P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
HUE026820T2 true HUE026820T2 (en) 2016-07-28

Family

ID=38668152

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE07804842A HUE026820T2 (en) 2006-05-09 2007-05-09 The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders

Country Status (12)

Country Link
US (3) US20090306214A1 (enExample)
EP (1) EP2026775B1 (enExample)
JP (1) JP5225264B2 (enExample)
AU (1) AU2007246779B2 (enExample)
CA (1) CA2651375C (enExample)
DK (1) DK2026775T3 (enExample)
ES (1) ES2542344T3 (enExample)
HU (1) HUE026820T2 (enExample)
IL (1) IL195152A (enExample)
PL (1) PL2026775T3 (enExample)
PT (1) PT2026775E (enExample)
WO (1) WO2007129226A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031129A2 (en) * 2002-10-03 2004-04-15 New Era Biotech, Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
CA2560922C (en) * 2004-03-26 2014-01-07 New Era Biotech, Ltd. Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions
GB0804213D0 (en) * 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
PL2475361T3 (pl) * 2009-09-09 2020-07-13 Novaremed Ltd. N-podstawione benzenopropanoamidy do stosowania w leczeniu bólu i stanu zapalnego
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
ES2834638T3 (es) 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12605387B2 (en) 2020-07-24 2026-04-21 Secura Bio, Inc. Treatment of cancers using PI3 kinase isoform modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1908322A (en) * 1932-04-07 1933-05-09 Claude R Cook Weed puller
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2004031129A2 (en) * 2002-10-03 2004-04-15 New Era Biotech, Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
CA2560922C (en) * 2004-03-26 2014-01-07 New Era Biotech, Ltd. Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions

Also Published As

Publication number Publication date
US20090306214A1 (en) 2009-12-10
EP2026775B1 (en) 2015-04-29
WO2007129226A2 (en) 2007-11-15
US20140039060A1 (en) 2014-02-06
AU2007246779B2 (en) 2013-11-28
EP2026775A2 (en) 2009-02-25
IL195152A (en) 2015-10-29
AU2007246779A1 (en) 2007-11-15
US20120108666A1 (en) 2012-05-03
JP2009536191A (ja) 2009-10-08
ES2542344T3 (es) 2015-08-04
JP5225264B2 (ja) 2013-07-03
DK2026775T3 (en) 2015-06-29
WO2007129226A3 (en) 2008-05-08
IL195152A0 (en) 2009-09-22
CA2651375C (en) 2015-12-22
PT2026775E (pt) 2015-08-05
CA2651375A1 (en) 2007-11-15
PL2026775T3 (pl) 2015-12-31

Similar Documents

Publication Publication Date Title
DK2026775T3 (en) USE OF SYK tyrosine kinase inhibitors for treating cell proliferative DISORDERS
JPH07228558A (ja) スチルベン誘導体及びそれを含有する制癌剤
KR20050059094A (ko) 4-플루오로-2-시아노피롤리딘 유도체 벤젠술폰산염
JP6758669B2 (ja) アスコクロリン誘導体およびampk活性化剤としてのその使用
WO2023141852A1 (zh) Cdk2抑制剂及其制备方法和用途
EP1750691B1 (en) Compounds for treatment of aids and other diseases
US6011069A (en) Multidrug resistance inhibitors
JP7734361B2 (ja) 化合物又はその塩及びその製造方法、化合物又はその塩を含む医薬品組成物及びその製造方法
JP4604161B2 (ja) フェニルアラニン誘導体
US7572778B2 (en) Fluorocombretastatin and derivatives thereof
JPH024748A (ja) 薬理作用を有するペプチド類
CN103450164B (zh) 格尔德霉素衍生物及其制备方法和用途
WO1994008947A1 (fr) Nouveau derive aminoacide
CA3303518A1 (en) Compound or salt thereof and method for producing the same, pharmaceutical composition comprising the compound or salt thereof and method for producing the same
HK1161872A (en) New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties